Polar Asset Management Partners’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Polar Asset Management Partners’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$114K	Hold	1,900,000	–	–	﹤0.01%	510
2025 Q4	$356K	Hold	1,900,000	–	–	﹤0.01%	481
2025 Q3	$413K	Hold	1,900,000	–	–	﹤0.01%	471
2025 Q2	$228K	Hold	1,900,000	–	–	﹤0.01%	435
2025 Q1	$247K	Buy	+1,900,000	New	+$267K	0.01%	362

Other funds holding DMAAR

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Polar Asset Management Partners's DMAAR Position: Q1 2026 in Review

Polar Asset Management Partners held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q1 2026 at 1,900,000 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #510.

Polar Asset Management Partners first reported a position in DMAAR in Q1 2025 and has held it in 5 quarters since. The position peaked at $413K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

Polar Asset Management Partners held 1,900,000 shares of Drugs Made In America Acquisition Corp Rights worth $114K as of Q1 2026.
Polar Asset Management Partners left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q1 2026.
Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Polar Asset Management Partners's portfolio in Q1 2026, its #510 holding.
Polar Asset Management Partners first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 5 quarters since.
Polar Asset Management Partners's Drugs Made In America Acquisition Corp Rights position peaked at $413K in Q3 2025.
35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Polar Asset Management Partners's 13F filing for Q1 2026, filed 15 May 2026.